Extrahepatic bile duct leiomyosarcoma

Summary

Extrahepatic bile duct leiomyosarcoma (MONDO:0003377) is a disease. A subtype of extrahepatic bile duct carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	extrahepatic bile duct leiomyosarcoma
Mondo ID	MONDO:0003377
DOID	DOID:5293
NCIT	C5848
UMLS	C1333508
MedGen	232481
GARD	0023489
Anatomy (UBERON)	UBERON:0003703
Is cancer (heuristic)	no

Also known as: bile duct leiomyosarcoma · extrahepatic bile duct leiomyosarcoma · leiomyosarcoma of bile duct · leiomyosarcoma of extrahepatic bile duct · leiomyosarcoma of the bile duct · leiomyosarcoma of the extrahepatic bile duct

Disease family

This is a subtype of extrahepatic bile duct carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › bile duct carcinoma › extrahepatic bile duct carcinoma › extrahepatic bile duct leiomyosarcoma

Related subtypes (5): extrahepatic bile duct adenocarcinoma, distal biliary tract carcinoma, extrahepatic bile duct squamous cell carcinoma, carcinoma of the ampulla of vater, carcinoma in situ of extrahepatic bile duct

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.